ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) persists its position slightly strong in context of buying side, while shares price ascend 21.43% during latest trading session. ContraVir Pharmaceuticals, Inc. (CTRV) reported positive interim data for CMX157, the Firm’s highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead’s Viread) in chronically infected hepatitis B (HBV) patients.
“We are happy and excited with these clinical results, as they demonstrate CMX157’s great potential in our ongoing effort to develop a cure for HBV,” stated James Sapirstein, CEO of ContraVir.
Narrow down focus to other ratios, the co has current ratio of 1.60 that indicates if CTRV lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 1.60, which indicates firm has sufficient short-term assets to cover its immediate liabilities.
Following previous ticker characteristics, Rexahn Pharmaceuticals, Inc. (NYSE:RNN) also run on active notice, stock price moved down -9.15% after traded at $0.18 in most recent trading session.
RNN price to current year EPS stands at 25.00%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 85.70%. Moving toward ratio analysis, it has current ratio of 11.40 and quick ratio was calculated as 11.40. The debt to equity ratio appeared as 0.00 for seeing its liquidity position.
Taking notice on volatility measures, price volatility of stock was 8.31% for a week and 6.23% for a month. The price volatility’s Average True Range for 14 days was 0.01. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 1.50 out of 1-5 scale with week’s performance of -14.77%. RNN’s institutional ownership was registered as 14.30%, while insider ownership was 4.19%.